ArticlePloS one2016
Virus-Like Nanoparticle Vaccine Confers Protection against Toxoplasma gondii.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 32 citations in OpenAlex.
- Nanoparticle-Based Vaccines Against Toxoplasma gondii: Immunological Rationale, Platform Strategies, and Translational Challenges.Transboundary and emerging diseases · 2026Review
- Applications of virus-like particles in the prevention of protozoan parasite infection.Nanomedicine (London, England) · 2025Review
- Article
- Correction: Virus-Like Nanoparticle Vaccine Confers Protection against Toxoplasma gondii.PloS one · 2024Article
- Nanoparticles as a Delivery System of Antigens for the Development of an Effective Vaccine againstVaccines · 2023Review
- Virus-like Particle Vaccine Expressing the Respiratory Syncytial Virus Pre-Fusion and G Proteins Confers Protection against RSV Challenge Infection.Pharmaceutics · 2023Article
- Toxoplasma gondii vaccine candidates: a concise review.Irish journal of medical science · 2023Review
- Using Self-Assembling ADDomer Platform to Display B and T Epitopes of Type O Foot-and-Mouth Disease Virus.Viruses · 2022Article
- Protection and Alleviated Inflammation Induced by Virus-like Particle Vaccines ContainingVaccines · 2022Article
- Detection of Toxoplasma gondii Infections using Virus-Like Particles Displaying T. gondii ROP4 Antigen.The Korean journal of parasitology · 2021Article
- [Toxoplasma gondii-Current drugs and future vaccines against an underestimated protozoan infection].Der Internist · 2021Review
- Article
- Advances inVaccines · 2021Review
- Virus-Like Particle Vaccines Against Respiratory Viruses and Protozoan Parasites.Current topics in microbiology and immunology · 2021Review
- Evaluation of CpG-ODN-AdjuvantedPharmaceutics · 2020Article
- Protective Immunity Induced by Virus-Like Particle Containing Merozoite Surface Protein 9 ofVaccines · 2020Article
- Protection induced by malaria virus-like particles containing codon-optimized AMA-1 of Plasmodium berghei.Malaria journal · 2019Article
- Influenza Virus-Like Particles Presenting bothPharmaceutics · 2019Article
- Previous Infection with Plasmodium berghei Confers Resistance to Toxoplasma gondii Infection in Mice.The Korean journal of parasitology · 2019Article
- Virus-like particles containing multiple antigenic proteins of Toxoplasma gondii induce memory T cell and B cell responses.PloS one · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The inner membrane complex (IMC) of Toxoplasma gondii as a peripheral membrane system has unique and critical roles in parasite replication, motility and invasion. Disruption of IMC sub-compartment protein produces a severe defect in T. gondii endodyogeny, the form of internal cell budding. In this study, we generated T. gondii virus-like particle particles (VLPs) containing proteins derived from IMC, and investigated their efficacy as a vaccine in mice. VLP vaccination induced Toxoplasma gondii-specific total IgG, IgG1 and IgG2a antibody responses in the sera and IgA antibody responses in the feces. Upon challenge infection with a lethal dose of T. gondii (ME49), all vaccinated mice survived, whereas all naïve control mice died. Vaccinated mice showed significantly reduced cyst load and cyst size in the brain. VLP vaccination also induced IgA and IgG antibody responses in feces and intestines, and antibody-secreting plasma cells, mixed Th1/Th2 cytokines and CD4+/CD8+ T cells from spleen. Taken together, these results indicate that non-replicating VLPs containing inner membrane complex of T. gondii represent a promising strategy for the development of a safe and effective vaccine to control the spread of Toxoplasma gondii infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.